Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin
- PMID: 9300576
- DOI: 10.1097/00001813-199707000-00009
Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin
Abstract
We have studied the cytotoxicity and intracellular accumulation of two lipophilic anthracyclines, pirarubicin and idarubicin, as compared to doxorubicin, in two human tumor cell lines, MCF7 and K562, and in their doxorubicin-resistant counterparts, presenting the multidrug-resistant (MDR) phenotype. The new lipophilic anthracyclines were found to present a higher cytotoxicity and accumulation than the reference anthracycline, doxorubicin, and there was a significant inverse correlation between drug accumulation and IC50 in both cell types. With the aim of identifying the reasons for the higher cytotoxicity and accumulation of lipophilic anthracyclines, we used and compared the efficiency of three MDR modulators, verapamil, quinine and S-9788. We showed that all three were able to sensitize the resistant cells to the three anthracyclines, but with different efficiencies, S-9788 being the most active reverter and quinine the least active at equimolar doses. We also observed that there was no correlation between the abilities of a modulator to reverse resistance and to restore drug accumulation. In view of the sustained activity of the modulators to increase pirarubicin and idarubicin cytotoxicity and accumulation, as they do for doxorubicin, we conclude that the better efficiency of lipophilic anthracyclines is likely to be due to their high uptake rate rather than to a decreased activity of P-glycoprotein on these drug substrates.
Similar articles
-
The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.Eur J Pharmacol. 1998 Feb 19;343(2-3):313-21. doi: 10.1016/s0014-2999(97)01548-3. Eur J Pharmacol. 1998. PMID: 9570481
-
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.Blood. 1996 Jul 15;88(2):633-44. Blood. 1996. PMID: 8695811
-
Pirarubicin nuclear uptake does not correlate with its induced cell death effect during reversal of multidrug resistance by quinine in human K562 and CEM leukemic cells.Eur J Haematol. 1998 Oct;61(4):240-9. doi: 10.1111/j.1600-0609.1998.tb01709.x. Eur J Haematol. 1998. PMID: 9820630
-
[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].Bull Cancer. 1997 Apr;84(4):343-9. Bull Cancer. 1997. PMID: 9238156 Review. French.
-
[Pharmacokinetics of new anthracyclines].Bull Cancer. 1988;75(2):167-74. Bull Cancer. 1988. PMID: 3282579 Review. French.
Cited by
-
Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.Invest New Drugs. 2002 Feb;20(1):35-48. doi: 10.1023/a:1014415205955. Invest New Drugs. 2002. PMID: 12003193
-
Synergy between verapamil and other multidrug -resistance modulators in model membranes.J Biosci. 2007 Jun;32(4):737-46. doi: 10.1007/s12038-007-0073-5. J Biosci. 2007. PMID: 17762146
-
Review of the Delivery Kinetics of Thermosensitive Liposomes.Cancers (Basel). 2023 Jan 7;15(2):398. doi: 10.3390/cancers15020398. Cancers (Basel). 2023. PMID: 36672347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources